Home Page
About us
- Overview
- Organization
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
Corporate Gouvernance
- General annual meetings
- Board of Directors and Management
Investors Relations
- Reports
News
- Press Releases
- Publications, conferences & press
Contact

Oblique Therapeutics > News > 2019 > March

Home Page
About us
- Overview
- Organization
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
Corporate Gouvernance
- General annual meetings
- Board of Directors and Management
Investors Relations
- Reports
News
- Press Releases
- Publications, conferences & press
Contact

News

Archive

November 2020
October 2020
September 2020
June 2020
November 2019
October 2019
July 2019
March 2019
January 2019
November 2018
October 2018
September 2018

Categories

Company updates
News

28 Mar 2019

We welcome our new owners

07 Mar 2019

New collaboration with Pharma

Copyright © 2021 Oblique Therapeutics AB.

Contact

Oblique Therapeutics AB
info@obliquet.com

Gothenburg
Arvid Wallgrens Backe 20
413 46 Göteborg
Sweden

Stockholm
Döbelnsgatan 64
113 52 Stockholm
Sweden

Menu

Home Page
About us
- Overview
- Organization
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
Corporate Gouvernance
- General annual meetings
- Board of Directors and Management
Investors Relations
- Reports
News
- Press Releases
- Publications, conferences & press
Contact

About

Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome.

We use cookies to improve the user experience on Oblique Therapeutics. Read more about Cookies

Approve